Oncology Research Information Exchange Network in Improving Genetic Screening Rate in Patients With Cancer

Study Overview
=================
Brief Summary
-----------------
This research trial studies how well Oncology Research Information Exchange Network (ORIEN) works in improving genetic screening rate in patients with cancer. Implementation of Progeny Genetic Pedigree and Family History Questionnaire software across all ORIEN member institutions may add value and utility for recognizing and caring for patients with an inherited susceptibility to cancer.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. Measure the change in uptake of cancer genetic referrals and genetic testing in the ORIEN system of cancer centers implementing the Progeny Family History Questionnaire (FHQ). SECONDARY OBJECTIVES: I. Follow and estimate utilization of preventive health behaviors among Progeny FHQ users across all institutions. II. Compare utilization of preventive health behavior between Progeny FHQ risk identification and genetic testing. OUTLINE: Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation. After completion of study, patients are followed up at 6 months after disclosure of genetic testing results.

Official Title
-----------------
ORIEN-PROGENY Family History Questionnaire Study: Recognizing Inherited Susceptibility to Cancer

Conditions
-----------------
Malignant Neoplasm

Intervention / Treatment
-----------------
* Other: Questionnaire Administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Limited to those patients who are consented to the Total Cancer Care Protocol (TCCP) protocol Able to understand and sign the TCCP informed consent, California subject?s bill of rights, Health Insurance Portability and Accountability Act (HIPAA), and research authorization form directly or through an authorized representative; the informed consent, subject?s bill of rights, HIPAA, and research authorization will be available in both English and Spanish languages Exclusion Criteria: Individuals who are not registered as patients for outpatient or inpatient care to the TCCP protocol Individuals who are unable to understand or sign the TCCP informed consent, subject?s bill of rights, HIPAA, and research authorization in either English or Spanish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-Correlative (questionnaire)<br>Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation. | Other: Questionnaire Administration<br>* Ancillary studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Rates of Genetic Testing | Will compare rates of genetic testing before and after implementation of Progeny Family History Questionnaire (FHQ) using the stratified Chi-square test. | Up to 30 months |